UY26696A1 - Método para regular la angiogénesis utilizando proteína ryk - Google Patents

Método para regular la angiogénesis utilizando proteína ryk

Info

Publication number
UY26696A1
UY26696A1 UY26696A UY26696A UY26696A1 UY 26696 A1 UY26696 A1 UY 26696A1 UY 26696 A UY26696 A UY 26696A UY 26696 A UY26696 A UY 26696A UY 26696 A1 UY26696 A1 UY 26696A1
Authority
UY
Uruguay
Prior art keywords
ryk
anglogenesis
proteins
diseases
protein
Prior art date
Application number
UY26696A
Other languages
English (en)
Spanish (es)
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY26696A1 publication Critical patent/UY26696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY26696A 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk UY26696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
UY26696A1 true UY26696A1 (es) 2001-12-28

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26696A UY26696A1 (es) 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (ja)
JP (1) JP2004527206A (ja)
AR (1) AR028424A1 (ja)
AU (1) AU2001261343A1 (ja)
CA (1) CA2408349A1 (ja)
CO (1) CO5300464A1 (ja)
DO (1) DOP2001000164A (ja)
EC (1) ECSP014068A (ja)
GT (1) GT200100079A (ja)
PE (1) PE20011218A1 (ja)
SV (1) SV2002000442A (ja)
UY (1) UY26696A1 (ja)
WO (1) WO2001085789A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516608A (ja) * 2002-02-06 2005-06-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング エネルギー恒常性の調節に関与するキナーゼ
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
MX2017000840A (es) 2014-07-18 2017-05-04 Sanofi Sa Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646129A4 (en) * 1992-05-11 1995-07-19 Ludwig Inst Cancer Res MOLECULES, WHICH ARE SIMILAR TO THE TYROSIN KINASE OF THE RECEPTOR TYPE (01/13/94).
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
ATE321856T1 (de) * 1998-06-11 2006-04-15 Humane rezeptortyrosinkinase
CA2348835A1 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
ECSP014068A (es) 2002-02-25
SV2002000442A (es) 2002-07-03
DOP2001000164A (es) 2002-05-15
WO2001085789A2 (en) 2001-11-15
CA2408349A1 (en) 2001-11-15
PE20011218A1 (es) 2002-02-01
EP1287121A2 (en) 2003-03-05
WO2001085789A3 (en) 2002-05-16
AU2001261343A1 (en) 2001-11-20
AR028424A1 (es) 2003-05-07
JP2004527206A (ja) 2004-09-09
GT200100079A (es) 2001-12-31
CO5300464A1 (es) 2003-07-31

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ES2080837T3 (es) Tratamiento de estados y enfermedades.
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
Tak et al. Oral submucous fibrosis: A review article on etiopathogenesis
UY26696A1 (es) Método para regular la angiogénesis utilizando proteína ryk
PT1343472E (pt) Pulverizacao nasal tixotropica
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
Matthews-Brzozowska et al. Revitalization of facial skin based on preparations of patient own blood
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
ATE283058T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von dysphorie
UY26649A1 (es) Proteína que tiene actividad moduladora de angiogenesis
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
CN101732325A (zh) 一种可用于皮肤创伤修复的药物
SV2002000362A (es) Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv
Sajjad et al. The The Therapeutic Effects of Autologous Platelet-Rich Plasma Gel on Cutaneous Wound Healing in Rescued Horses: The Effects of Autologous Platelet-Rich Plasma Gel on skin Wound Healing in Horses
Weiss et al. Molecules in focus Endothelial cell stimulating angiogenesis factor
US20230038408A1 (en) Biophotonic compositions, uses and methods for modulating mitochondrial dynamics and functionality in skin and soft tissue conditions
ATE312173T1 (de) Methoden und zusammensetzungen zur aufklärung von proteinexpressionsprofilen in zellen
ATE302000T1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
Dhayalan et al. Diabetic foot ulceration and Wound Healing Dressing materials

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20131119